Early Insight Into the Retrospective Data of a Case Series on Type 2 Diabetes Mellitus on Alternate-Day Dosing of Oral Semaglutide: Utopia or Reality?

Autor:	RoyChaudhuri S; Endocrinology, Kali Prasad Chowdhury Medical College & Hospital, Kolkata, IND., Majumder A; Endocrinology, Kali Prasad Chowdhury Medical College & Hospital, Kolkata, IND., Sanyal D; Endocrinology, Kali Prasad Chowdhury Medical College & Hospital, Kolkata, IND., Chakraborty S; Nutrition, Diabetes-Obesity-Thyroid-Hormone Clinic, Kolkata, IND., Chuyan S; Diabetes Educator, Adopt Endocrine Diabetes Care, Kolkata, IND.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2023 Apr 03; Vol. 15 (4), pp. e37065. Date of Electronic Publication: 2023 Apr 03 (Print Publication: 2023).
DOI:	10.7759/cureus.37065
Abstrakt:	Introduction Oral semaglutide, with a long half-life of seven days, is the first oral-based peptide drug and is used as an antidiabetic for the reduction of glycosylated hemoglobin (HbA1c). Oral semaglutide, like other glucagon-like peptide-1 receptor agonists (GLP1RAs), is costly and has gastrointestinal (GI) side effects, especially with a 14 mg dose. In the real world, some type 2 diabetes mellitus (T2DM) patients on 14 mg oral dose adopt an alternate-day strategy to minimize unwanted GI symptoms. In this study, we analyzed the ambulatory glucose profile (AGP) data of patients with T2DM who were on 14 mg alternate-day oral semaglutide therapy. Methods This retrospective observational study evaluated the AGP data of 10 patients on alternate-day dosing of 14 mg oral semaglutide. The AGP data over a period of 14 days on a single group of patients were analyzed without any control group or randomization and are presented as a case series. AGP monitoring, using Freestyle Libre Pro (Abbott, Illinois, United States), is a standard operating procedure of the endocrinology department for all T2DM patients who were put on oral semaglutide therapy. The AGP data of the glycemic parameters time-in-range (TIR), time-above-range (TAR), and time-below-range (TBR), were compared between the days when oral semaglutide was consumed (days-on-drug) versus the days when oral semaglutide was not consumed (days-off-drug). The statistical analysis was done with Statistical Package for Social Sciences (SPSS) version 21.0 (IBM Corp., Armonk, NY). Results We applied the Shapiro-Wilk test (sample size <50) for normality testing; the TIR values of days-on-drug and days-off-drug showed high p values (p =0.285 and 0.109), respectively. This indicated that TIR values days-on-drug and days-off-drug were normally distributed. Although, the distribution of TAR and TBR values days-on-drug and days-off-drug, were not normal as they had small p values (p< 0.05). Hence, further analysis of the paired set of data was done using the Wilcoxon signed-rank test. It revealed no difference in TIR, TAR, and TBR between the two groups (days-on-drug and days-off-drug). Conclusion Throughout the period of observation, the glycemic metrics (TIR, TAR, and TBR) remained steady with a 14 mg alternate-day oral semaglutide regimen. Competing Interests: The authors have declared financial relationships, which are detailed in the next section. (Copyright © 2023, RoyChaudhuri et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu